ClinicalTrials.gg
Active, not recruitingNCT07377136Obesity UroAUpdated Oct 26, 2026

Influence of the Urolithin A on the Population With BMI Higher Than 30 During Restricted Eating.

An interventional study of Urolithin A 500mg and Placebo in Obesity & Overweight, sponsored by Charles University, Czech Republic. Active, not recruiting at 1 site in Czechia. Open to participants aged 30 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Charles University, Czech Republic · Not applicable, Interventional, and Treatment

How we know

Updated Oct 26, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
30 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 97 studies in Obesity with a site in Czechia — 26 open to participants now, 46 under way, 32 of them phase 3. Obesity · Czechia.

Enrollment
62nd of 88
102 · median 478
Started
2025
with 20 others
No phase
33 of 97
7 open now
Primary completion
2026-08
later than 4 of 45 live
Registered
74th of 97
by date
Lead sponsor
7 of 97
Charles University, Czech Republic

Among the 97 studies in Obesity with a site in Czechia, this one is the 62nd largest by enrollment of the 88 interventional ones that give a count, is one of 21 that started in 2025, is one of 33 with no phase, reaches primary completion later than 4 of the 45 other live ones, and was the 74th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

26 of the 97 studies in Obesity with a site in Czechia are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 30 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies in Obesity with a site in Czechia, or all of them as a file.
02

Study summary

Purpose. This study will test whether daily Urolithin A (500 mg) for 6 months helps adults with obesity lose weight while preserving functional muscle mass and improving markers of mitochondrial health, inflammation, and metabolism. All participants receive the same structured lifestyle program (nutrition and sleep guidance); half will receive Urolithin A and half a matching placebo.

Background. Weight loss can improve health but may also reduce skeletal muscle, especially in people with obesity. Aging and obesity are both linked to mitochondrial dysfunction, impaired autophagy/mitophagy, oxidative stress, and low-grade inflammation. Urolithin A is a gut-derived, diet-related compound that promotes mitophagy and may support muscle function and metabolic health.

Design. Single-center, randomized, placebo-controlled, parallel-group trial. About 100 adults aged 30-60 years with BMI >30 kg/m² and elevated visceral adiposity will be enrolled and randomized in a 1:1 ratio (stratified by sex and age ≤45 vs ≥45 years). Blinding will include participants, study staff, and assessors.

Intervention.

Urolithin A 500 mg orally once daily vs matching placebo, for 24 weeks.

A standardized lifestyle program for all participants: individualized energy restriction with higher protein intake, reduced carbohydrates, and time-restricted eating (11-hour eating window / 13-hour overnight fast); plus structured sleep-hygiene recommendations and light daily activity guidance.

No other dietary supplements are allowed during the study.

Main assessments. At baseline and regularly during the study, participants will undergo:

Body composition by bioimpedance (InBody), including skeletal muscle and visceral fat indices.

Muscle function (handgrip dynamometry; 30-second chair-stand).

Cardiometabolic and inflammatory biomarkers from blood (standard biochemistry, lipids, glucose/HbA1c, CRP; exploratory cytokines/adipokines).

Mitochondrial/aging biomarkers, including DNA-based epigenetic aging measures.

Cardiovascular/ANS function (heart-rate variability and vascular indices; MaxPulse Medicore).

Questionnaires on sleep quality, physical activity, and weight-management self-efficacy.

Visits and duration. 6-month participation with baseline, 3-weekly check-ins, and a final visit for repeat testing and blood sampling.

Outcomes. The study focuses on safety and on whether Urolithin A, compared with placebo, helps preserve functional muscle mass and improves mitochondrial, inflammatory, and metabolic biomarkers during weight loss.

Who can join. Adults 30-60 years with obesity and higher visceral fat who are willing to follow the lifestyle program. Key medical exclusions (e.g., diabetes, active autoimmune disease, pregnancy) and supplement restrictions apply; full criteria are provided in the Eligibility section.

Potential benefits and risks. Participants may benefit from weight loss support and close monitoring. Risks include blood draw discomfort and potential, usually mild, supplement-related side effects. Safety will be monitored throughout.

Location and sponsor. The study is conducted at Charles University, Faculty of Medicine in Hradec Králové (Czech Republic) under the Department of Preventive Medicine.

Read the detailed description

Scientific Background and Rationale

Obesity and aging share pathophysiological features-mitochondrial dysfunction, impaired autophagy/mitophagy, oxidative stress, and chronic low-grade inflammation-that contribute to loss of skeletal muscle and functional capacity ("sarcopenic obesity") and increased frailty risk. While weight reduction improves cardiometabolic health, it can also decrease lean mass if not carefully managed.

Urolithin A (UA) is a bioactive metabolite derived from ellagitannins that has shown the ability to activate mitophagy, support mitochondrial function, and favor muscle health in preclinical and early clinical studies. We hypothesize that, when combined with a standardized lifestyle program, UA 500 mg/day will preserve functional muscle mass and favorable biomarker profiles during intentional weight loss in adults with obesity.

Objectives

Primary objective:

Evaluate the safety and efficacy of 6 months of Urolithin A 500 mg once daily versus placebo, in addition to a structured lifestyle program, in adults with obesity undergoing dietary restriction. Efficacy focuses on preservation of functional muscle mass in the context of weight loss and on improvements in biomarkers of mitochondrial function, inflammation, and metabolic health.

Key secondary objectives:

Quantify changes in body composition (skeletal muscle mass; visceral adiposity) over time.

Assess muscle strength and endurance (handgrip dynamometry; 30-second chair-stand).

Evaluate systemic inflammatory and oxidative-stress markers and metabolic profile (e.g., lipids, glucose/HbA1c, CRP).

Explore the impact on biological aging using validated epigenetic aging and related molecular biomarkers.

Characterize changes in autonomic/vascular indices (e.g., HRV, arterial elasticity) and patient-reported outcomes (sleep, activity, weight-management self-efficacy).

Examine associations between lifestyle adherence and outcomes.

Study Design

Prospective, single-center, randomized, placebo-controlled, parallel-group clinical trial with blinded participants, investigators, and outcome assessors. Target enrollment: \~100 participants (approximately balanced by sex and age group ≤45 vs ≥45 years via stratified randomization).

Arms and Interventions

Experimental (Urolithin A): Urolithin A 500 mg oral capsule once daily for 24 weeks.

Control (Placebo): Matching placebo capsule once daily for 24 weeks.

Co-intervention (both arms): A standardized lifestyle program tailored to baseline anthropometrics, comprising:

Energy restriction with higher protein intake (approx. 1.0-1.5 g/kg/day) and reduced carbohydrates; emphasis on minimally processed foods.

Time-restricted eating: 11-hour eating window with 13-hour overnight fast (e.g., \~08:00-19:00).

Sleep-hygiene optimization: regular bed/wake times; targets of 7.5-9 hours of nightly sleep; guidance on environment, light exposure, stimulants, and pre-sleep routines.

Light daily activity guidance. Use of other dietary supplements is prohibited during participation.

Schedule of Assessments

Screening / "Visit 0": Eligibility review; bioimpedance to confirm visceral fat level threshold; anthropometry; blood pressure.

Baseline (Day 0): Informed consent; questionnaires; blood sampling; bioimpedance (InBody); MaxPulse Medicore autonomic/vascular testing; muscle strength (handgrip dynamometry, average of 3 trials + peak value) and muscle endurance (30-second chair-stand); individualized nutrition and sleep-hygiene education.

Follow-ups: Approximately every 3 weeks-anthropometry, blood pressure, bioimpedance, MaxPulse Medicore, muscle testing, adherence review, and lifestyle adjustments as needed.

End of Study (Week 24): Repeat baseline assessments and final blood sampling; exit interview.

Outcome Domains (entered in detail in the Outcomes module)

Functional muscle preservation: bioimpedance-derived skeletal muscle indices; handgrip strength; chair-stand repetitions.

Body composition: total fat mass; visceral adipose area/score; segmental lean/fat distribution.

Cardiometabolic/Inflammatory biomarkers: standard biochemistry (electrolytes, liver/kidney function, lipids, glucose/HbA1c, CRP) and exploratory panels (e.g., TNF-α, IL-6, adipokines, myostatin, SIRT1, endothelial adhesion molecules).

Mitochondrial/healthy aging measures: DNA-based epigenetic aging clocks and related molecular markers from whole blood.

Autonomic/vascular function: HRV metrics, arterial elasticity, and vascular flow indices via MaxPulse Medicore.

Patient-reported outcomes: sleep quality (PSQI), physical activity (GPAQ), and weight-management self-efficacy (WEL).

Eligibility (summary; see Eligibility module for full criteria)

Adults 30-60 years with BMI >30 kg/m² and elevated visceral fat by bioimpedance who can follow the lifestyle program. Key exclusions include thyroid disease, type 2 diabetes, autoimmune/inflammatory bowel disease, active malignancy, pregnancy/lactation or planned pregnancy, severe psychiatric disease limiting adherence, major uncontrolled comorbidities, significant musculoskeletal limitations, and use of dietary supplements other than the study product.

Randomization, Blinding, and Allocation Concealment

Participants will be randomized 1:1 to UA or placebo using a computer-generated sequence with stratification by sex and age. Identical capsules will be dispensed to maintain blinding of participants, site staff, and assessors. Emergency unblinding procedures will be in place.

Safety Monitoring

Adverse events (AEs), vitals, and laboratory parameters will be collected at each visit. Women of child-bearing potential will follow pregnancy precautions; pregnancy during the study leads to discontinuation of the investigational product and withdrawal from the trial. Pre-specified stopping rules include serious or unexpected adverse reactions deemed related to the study product. AEs/SAEs will be recorded and reported per applicable regulations.

Concomitant Medications and Prohibited Therapies

Stable chronic medications are permitted when clinically necessary; major changes (e.g., for hypertension) are allowed only as needed and will be documented. All non-study dietary supplements are prohibited during participation.

Adherence and Retention

Adherence will be supported through structured education, 3-weekly check-ins, and review of pill counts and lifestyle logs (nutrition, sleep, activity). Motivational elements include a brief written statement of goals at baseline.

Biospecimen Handling

Blood samples will be pseudonymized and processed according to standard operating procedures for clinical chemistry/hematology, ELISA panels (inflammation, adipokines, etc.), and DNA extraction for epigenetic analyses. Samples will be delivered to designated laboratories within defined processing windows.

Statistical Considerations

Analyses will follow intention-to-treat with a per-protocol sensitivity set. Continuous outcomes will be analyzed using ANCOVA or mixed-effects models with baseline values and stratification factors as covariates. Categorical outcomes will use appropriate models (e.g., χ² or logistic regression). Pre-specified subgroup analyses by sex and age group will be performed. With \~100 participants, the study is powered to detect a moderate effect size in body-composition/functional endpoints while characterizing safety and biomarker trajectories.

Ethics and Oversight

The protocol will receive Ethics Committee/IRB approval prior to enrollment. The trial will be conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. All participants will provide written informed consent. Data confidentiality will be maintained using coded identifiers and secure storage.

Expected Impact

If effective, Urolithin A could provide a simple, adjunctive strategy to protect muscle health and improve biological aging and metabolic markers during dietary weight loss in adults with obesity.

03

Conditions studied

  • Obesity & Overweight

Keywords

  • obesity
  • urolithinA
  • restricted eating
04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 30-60 years (inclusive) at screening
  • > 30 kg/m² at screening
  • Visceral fat level ≥ 12 by segmental bioimpedance (InBody) at screening
  • Able and willing to follow the standardized lifestyle program (individualized energy restriction with higher protein, reduced carbohydrates, time-restricted eating 11:13) and sleep-hygiene guidance for 24 weeks
  • Willing to attend baseline and \~3-weekly follow-ups; undergo blood draws, bioimpedance, MaxPulse testing, and muscle strength/endurance tests; and complete questionnaires (WEL, PSQI, GPAQ)
  • Medication stability: chronic medications (e.g., treated hypertension, antidepressants) stable for ≥3 months before baseline; only clinically necessary changes allowed during the study
  • Permitted conditions/therapies (if stable): common allergies/atopic eczema; food intolerances; and menopausal hormone therapy
  • Women of : negative pregnancy test at baseline; agreement to use highly effective contraception during the study and for 4 weeks after last dose; not breastfeeding
  • Able to provide written

Exclusion criteria

Exclusion Criteria:

  • Known thyroid disease (untreated/unstable hypothyroidism or hyperthyroidism)
  • Type 2 diabetes mellitus (diagnosed or on glucose-lowering therapy)
  • disease, including psoriasis
  • Inflammatory bowel disease or other chronic inflammatory GI disorders (e.g., Crohn's disease, celiac disease)
  • Dyslipidemia treated with statins
  • Pregnancy, lactation, or planned pregnancy during the study period
  • Active malignant disease
  • Cognitive impairment or neurodegenerative disease that may affect consent or adherence
  • Severe psychiatric disorder that would preclude participation (e.g., severe major depression) or unstable depression/medication changes within the past 3 months
  • Uncontrolled comorbidity or decompensated chronic disease (e.g., uncontrolled hypertension; systolic ≥175 mmHg at screening)
  • Severe or limiting musculoskeletal condition preventing participation in assessments or the lifestyle program
  • Use of non-study dietary supplements (vitamins, herbal/nutraceutical products) that the participant is unwilling or unable to discontinue from baseline through end of study
  • Known allergy/intolerance to Urolithin A or capsule
  • Any condition that, in the investigator's judgment, makes participation unsafe or could compromise data integrity
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
102 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Other: Placebo

  • Experimental
    Urolithin A

    Dietary Supplement: Urolithin A 500mg

Interventions

  • Dietary supplementUrolithin A SupplementStudies of Urolithin A SupplementUrolithin A Supplement pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dietary Supplement: Urolithin A (500 mg) - Intervention Description Oral Urolithin A 500 mg capsule once daily for 24 weeks, preferably with the first meal. GMP-manufactured product; identical capsule shell/appearance to placebo. No dose titration. No other dietary supplements allowed during participation. Adherence assessed by pill counts and visit logs; temporary interruption permitted for adverse events per protocol. Co-administered with the same standardized lifestyle program as the control arm.

  • OtherPlacebo

    Placebo Comparator: Matching Placebo - Intervention Description Matching inert capsule (no Urolithin A), same size, color, shell, and packaging as active product; once daily for 24 weeks with the first meal. Dispensed in coded kits to maintain masking. Participants receive the same lifestyle program as the active arm. Use of other dietary supplements is prohibited during the trial.

06

What researchers measure

Primary outcomes

  1. Change in Appendicular Skeletal Muscle Index (ASMI) by Bioimpedance

    ASMI = sum of lean mass in both arms and legs (kg) divided by height² (m²), derived from segmental bioimpedance (InBody). Primary comparison is change from baseline to Week 24 between Urolithin A and placebo using ANCOVA adjusting for baseline, sex, and age stratum. Higher ASMI reflects greater functional muscle mass.

    Time frame: Baseline to Week 24 (end of intervention)

Secondary outcomes

  1. Change in Handgrip Strength (kg)

    Dominant-hand grip strength measured with a calibrated handheld dynamometer; average of 3 trials (peak also recorded). Between-group difference in change from baseline to Week 24.

    Time frame: Baseline to Week 24

  2. Change in Visceral Adipose Area (cm²) by Bioimpedance

    Visceral fat area (VFA, cm²) from InBody bioimpedance. Lower values indicate improvement. Between-group difference in change from baseline to Week 24.

    Time frame: Baseline to Week 24

  3. Change in Percent Body Fat (%)

    Whole-body fat percentage by bioimpedance (InBody). Between-group difference in change from baseline to Week 24.

    Time frame: Baseline to Week 24

  4. Glycemic Control (HbA1c)

    Change from baseline in HbA1c (%). Between-group difference (Urolithin A vs placebo) in change to Week 24 (ANCOVA with baseline, sex, age stratum).

    Time frame: Baseline to Week 24

  5. LDL-C

    Change from baseline in LDL-C. Between-group difference in change to Week 24.

    Time frame: Baseline to Week 24

  6. Inflammation (suPAR)

    Change from baseline in systemic inflammatory marker (suPAR; ng/mL). Between-group difference in change to Week 24.

    Time frame: Baseline to Week 24

  7. GDF15

    Change from baseline in serum GDF15 (assay units). Between-group difference in change to Week 24.

    Time frame: Baseline to Week 24

  8. Autonomic/Vascular Function (Arterial Elasticity)

    Change from baseline arterial elasticity score (MaxPulse Medicore). Between-group difference in change to Week 24.

    Time frame: Baseline to Week 24

  9. Epigenetic Aging Panel (DNA Methylation Age Acceleration)

    Change from baseline in blood-based DNA methylation age acceleration (years; difference between DNAm age and chronological age, specifically HorvathClock). Between-group difference in change to Week 24.

    Time frame: Baseline to Week 24

  10. Weight-Loss Responder Rates (≥5% and ≥10% Body Weight)

    Proportion of participants achieving ≥5% and ≥10% reduction from baseline body weight. Between-group comparison at Week 24.

    Time frame: Baseline to Week 24

  11. Patient-Reported Outcomes Panel (WEL)

    Change from baseline in Weight Efficacy Lifestyle Questionnaire total score (WEL). Between-group difference in change to Week 24.

    Time frame: Baseline to Week 24

  12. Patient-Reported Outcomes Panel (PSQI)

    Change from baseline in Pittsburgh Sleep Quality Index total score (PSQI). Between-group difference in change to Week 24.

    Time frame: Baseline to Week 24

  13. Patient-Reported Outcomes Panel (GPAQ)

    Change from baseline in Global Physical Activity Questionnaire total MET-minutes/week (GPAQ). Between-group difference in change to Week 24.

    Time frame: Baseline to week 24

  14. Safety Panel (TEAEs and SAEs)

    Participants with treatment-emergent adverse events and serious adverse events, coded by SOC/PT; severity and relatedness summarized by arm.

    Time frame: From first dose to Week 24

07

Study locations

1 site
  • Charles University, Faculty of Medicine in Hradec Kralove
    Hradec Králové, 500 03, Czechia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Aug 2026, 10 months.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 10 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Feb 2027, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2025
First posted
Jan 29, 2026
StartActual
Oct 8, 2025
Primary completionActual
Aug 14, 2026
CompletionEst.
Feb 28, 2027was Dec 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Active, not recruiting
changed Oct 26, 2026
Primary completion
Aug 30, 2026→Aug 14, 2026 (actual)
Oct 26, 2026
Study completion
Dec 31, 2026→Feb 28, 2027
Oct 26, 2026
Enrollment
100 (estimated)→102 (actual)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Enrolling by invitation→Active, not recruiting
    Primary completion Aug 30, 2026→Aug 14, 2026 (now actual)
    Study completion Dec 31, 2026→Feb 28, 2027
    Enrollment 100 (estimated)→102 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07377136
Responsible party
Pavel Borsky (Principal Investigator, Charles University, Czech Republic) — Principal investigator
First posted
Jan 29, 2026
Start date
Oct 8, 2025
Primary completion
Aug 14, 2026
Completion
Feb 28, 2027 (estimated)
Last update
Oct 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Urolithin A Supplement

Start the discussion